ATE305781T1 - Non-peptidische vasopressin via antagonisten - Google Patents

Non-peptidische vasopressin via antagonisten

Info

Publication number
ATE305781T1
ATE305781T1 AT97907895T AT97907895T ATE305781T1 AT E305781 T1 ATE305781 T1 AT E305781T1 AT 97907895 T AT97907895 T AT 97907895T AT 97907895 T AT97907895 T AT 97907895T AT E305781 T1 ATE305781 T1 AT E305781T1
Authority
AT
Austria
Prior art keywords
vasopressin via
via antagonists
peptidic vasopressin
peptidic
antagonists
Prior art date
Application number
AT97907895T
Other languages
German (de)
English (en)
Inventor
Robert F Bruns Jr
Robin D G Cooper
Bruce A Dressman
David C Hunden
Stephen W Kaldor
Gary A Koppel
John R Rizzo
Jeffrey James Skelton
Mitchell I Steinberg
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605046.3A external-priority patent/GB9605046D0/en
Priority claimed from GBGB9605045.5A external-priority patent/GB9605045D0/en
Priority claimed from GBGB9605044.8A external-priority patent/GB9605044D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE305781T1 publication Critical patent/ATE305781T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT97907895T 1996-02-23 1997-02-20 Non-peptidische vasopressin via antagonisten ATE305781T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1218896P 1996-02-23 1996-02-23
US1214996P 1996-02-23 1996-02-23
US1221596P 1996-02-23 1996-02-23
GBGB9605046.3A GB9605046D0 (en) 1996-03-09 1996-03-09 Method for antagonism of the tachykinin receptor with non-peptide agents
GBGB9605045.5A GB9605045D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the oxytocin receptor
GBGB9605044.8A GB9605044D0 (en) 1996-03-09 1996-03-09 Method and non-peptidyl agents for modulation of the vasopressin v1a receptor
PCT/US1997/003039 WO1997030707A1 (en) 1996-02-23 1997-02-20 NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE305781T1 true ATE305781T1 (de) 2005-10-15

Family

ID=27547258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907895T ATE305781T1 (de) 1996-02-23 1997-02-20 Non-peptidische vasopressin via antagonisten

Country Status (10)

Country Link
US (3) US6204260B1 (enExample)
EP (1) EP0939632B1 (enExample)
JP (1) JP4212112B2 (enExample)
AT (1) ATE305781T1 (enExample)
AU (1) AU1977997A (enExample)
CA (1) CA2246753C (enExample)
DE (1) DE69734321T2 (enExample)
DK (1) DK0939632T3 (enExample)
ES (1) ES2248840T3 (enExample)
WO (1) WO1997030707A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489319B2 (en) * 1999-08-16 2002-12-03 Revaax Pharmaceuticals, Llc Neurotherapeutic use of carboxypeptidase inhibitors
US6610681B1 (en) * 1999-08-16 2003-08-26 Revaax Pharmaceuticals, Llc Neurotherapeutic clavulanate composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
EP1226132A1 (en) 1999-11-04 2002-07-31 Ortho-McNeil Pharmaceutical, Inc. Nonpeptide substituted benzothiazepines as vasopressin antagonists
ATE360014T1 (de) 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
NZ532033A (en) * 2001-10-12 2006-11-30 Azevan Pharmaceuticals Inc 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives as vasopressin V1a receptor antagonists
AU2002359761A1 (en) * 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
BR0315053A (pt) * 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
TW200526651A (en) * 2003-10-03 2005-08-16 Serenix Pharmaceuticals Llc 3-substituted β-lactamyl vasopressin V1a antagonists
US7456176B2 (en) * 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
EP1868434A4 (en) * 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
AU2013206201B2 (en) * 2005-03-22 2016-06-16 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
CA2611720A1 (en) * 2005-06-08 2006-12-14 Targegen, Inc. Methods and compositions for the treatment of ocular disorders
TR201907381T4 (tr) * 2005-07-19 2019-06-21 Azevan Pharmaceuticals Inc Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) * 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007127366A2 (en) * 2006-04-25 2007-11-08 Targegen, Inc. Kinase inhibitors and methods of use thereof
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
MX2011011459A (es) * 2009-04-29 2011-11-18 Rexahn Pharmaceuticals Inc Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
ES2662350T3 (es) * 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2015237253B2 (en) 2014-03-28 2019-11-14 Azevan Pharmaceuticals, Inc. Compositions and methods for treating neurodegenerative diseases
MY208313A (en) 2017-09-15 2025-04-30 Azevan Pharmaceuticals Inc Compositions and methods for treating brain injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US4673737A (en) 1985-08-02 1987-06-16 Harvard University 7-acylamino-(or 7-amino)-3-trifluoromethylsulfonyloxy-1-carba(1-dethia)-3-cephem-4-carboxylic acids and esters thereof
DE3687870T2 (de) 1985-09-09 1993-08-19 Otsuka Pharma Co Ltd 2-oxa-isocephemverbindungen, sie enthaltende zusammensetzungen und verfahren zu deren herstellung.
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) * 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
KR960002856B1 (ko) 1987-03-09 1996-02-27 오쓰까 세이야꾸 가부시끼가이샤 2-옥사-이소세펨 화합물, 이를 함유하는 조성물 및 이의 제조방법
US5373089A (en) 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
US5068232A (en) * 1990-04-10 1991-11-26 American Cyanamid Company Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them
US5521307A (en) * 1992-02-18 1996-05-28 Eli Lilly And Company Methods and compounds for the preparation of carbacephems
JPH08502752A (ja) * 1992-10-27 1996-03-26 メルク エンド カンパニー インコーポレーテッド 抗炎症剤及び抗変性剤としての新規の置換アゼチジノン
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU4368896A (en) * 1994-11-23 1996-06-17 Affymax Technologies N.V. Methods for synthesizing diverse collections of beta-lactam compounds
DE69610978D1 (de) * 1995-03-31 2000-12-21 Naeja Pharmaceutical Inc 4-substituierte-3-peptidyl-azetidin-2-on-derivate als cystein-proteinase inhibitoren
WO1996035122A1 (en) * 1995-05-03 1996-11-07 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs

Also Published As

Publication number Publication date
JP4212112B2 (ja) 2009-01-21
US6204260B1 (en) 2001-03-20
EP0939632B1 (en) 2005-10-05
US20020049187A1 (en) 2002-04-25
AU1977997A (en) 1997-09-10
DE69734321T2 (de) 2006-08-10
DE69734321D1 (de) 2006-02-16
CA2246753C (en) 2005-05-10
JP2000504731A (ja) 2000-04-18
DK0939632T3 (da) 2006-01-30
EP0939632A4 (en) 2002-09-25
ES2248840T3 (es) 2006-03-16
US6610680B1 (en) 2003-08-26
CA2246753A1 (en) 1997-08-28
WO1997030707A1 (en) 1997-08-28
EP0939632A1 (en) 1999-09-08
US6521611B2 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
DE69734321D1 (de) Non-peptidische vasopressin via antagonisten
AU3998693A (en) Angiotensin ii antagonists
MX9703186A (es) Antagonistas del receptor del neuropeptido y de indolilo.
ES2179881T3 (es) Antagonistas de endotelina.
TR199802269T2 (xx) Endotelin resept�r antagonistleri olarak faydal� indol t�revleri.
AU2956095A (en) Heterocyclic tachykinin receptor antagonists
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
TR199801268T2 (xx) Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler.
DE69935873D1 (de) 2-Methyl-thieno-benzodiazepin Formulierung
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
ATE208764T1 (de) Isazole derivate als fibrinogen-rezeptor- antagonisten
DE69526738D1 (de) Endothelin-rezeptor-antagonisten
DK0900218T3 (da) Heterocykliske forbindelser
WO1998052548A3 (de) Verwendung von 1-ar(alk)yl-imidazolin-2-one zur behandlung von angst- und spannungszuständen
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
EA199800204A1 (ru) Антагонисты 5-нтрецепторов для лечения дискинезии
FI941117A0 (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
HK1008990A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0939632

Country of ref document: EP